Gynecologic cancer disparities in the United States

‘Getting the Village Back Together’: ChristianaCare’s Plan for Reducing Breast Cancer Disparities in Delaware

Retrieved on: 
Wednesday, November 1, 2023

Wilmington, Delaware, Nov. 01, 2023 (GLOBE NEWSWIRE) -- There’s a tried and proven pathway to reducing racial disparities in cancer in Delaware.

Key Points: 
  • Wilmington, Delaware, Nov. 01, 2023 (GLOBE NEWSWIRE) -- There’s a tried and proven pathway to reducing racial disparities in cancer in Delaware.
  • The commentary — "Reducing Racial Disparities in Breast Cancer: Getting the Village Back Together" — is a call to action for community members, health care providers and other stakeholders to partner together to address disparities in breast cancer.
  • According to the National Cancer Institute, Delaware leads the country in incidences of late-stage breast cancer among women younger than 50.
  • “We are excited at the possibility of bringing the larger village back together again to tackle the disparities in breast cancer.

iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta

Retrieved on: 
Monday, October 23, 2023

Elekta is taking over the business effective immediately and will make final payment no later than November 6, 2023.

Key Points: 
  • Elekta is taking over the business effective immediately and will make final payment no later than November 6, 2023.
  • By acquiring the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, Elekta will be able to offer electronic brachytherapy technology to provide expanded access to treatment for a range of cancers.
  • Xoft's unique technology provides targeted cancer care expertly tailored to meet patients’ personalized needs.
  • We are pleased that Elekta will be acquiring the Xoft subsidiary including both the technology and team,” said Dana Brown, President & CEO of iCAD.

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

Retrieved on: 
Friday, October 13, 2023

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor.
  • Lunresertib (RP-6306) is a first-in-class precision oncology small molecule PKMYT1 inhibitor that targets CCNE1 amplification, FBXW7 and PPP2R1A alterations in solid tumors.
  • Lunresertib is being evaluated alone and in combination with camonsertib (RP-3500 / RG6526), a potent and selective oral inhibitor of ATR developed by Repare and now partnered with Roche for development excluding the lunresertib + camonsertib combination.
  • “We saw early efficacy signals across multiple tumor types and in each genotype selected, most notably in gynecological tumors where the lunresertib + camonsertib combination provides a potential new treatment option for these patients.

Announcing Olink® Explore HT – A New Era in Proteomics

Retrieved on: 
Wednesday, July 12, 2023

Olink Explore HT represents a significant advancement in next generation proteomics, allowing scientists to accurately measure over 5,300 proteins using only 2µl of sample with a completely reimagined and streamlined workflow, including a highly automated data analysis platform.

Key Points: 
  • Olink Explore HT represents a significant advancement in next generation proteomics, allowing scientists to accurately measure over 5,300 proteins using only 2µl of sample with a completely reimagined and streamlined workflow, including a highly automated data analysis platform.
  • “Olink Explore HT demonstrates our unwavering commitment to innovation and delivering the most powerful solutions for scientific research,” said Jon Heimer, CEO of Olink.
  • “The power and capability of Olink Explore HT seemed almost unthinkable just a handful of years ago.
  • “Coupling PEA with an NGS readout conveys Olink Explore HT with unprecedented power to unveil the human proteome.

Burjeel Medical City Launches Advanced Gynecology Institute to Offer Complex Care Solutions for Women

Retrieved on: 
Tuesday, May 23, 2023

Burjeel Medical City, the flagship facility of Burjeel Holdings, has launched an Advanced Gynecology Institute (AGI) designed to offer multidisciplinary healthcare solutions to women of all ages.

Key Points: 
  • Burjeel Medical City, the flagship facility of Burjeel Holdings, has launched an Advanced Gynecology Institute (AGI) designed to offer multidisciplinary healthcare solutions to women of all ages.
  • Three specialized clinics of the hospital - Gynecological Oncology, IFEM Endo Middle East Clinic, and Complex Gynecology Care - will come under AGI.
  • Dr. Maitha Bint Salem Al Shamsi, Minister of State, UAE Government, inaugurating Advanced Gynecology Institute at Burjeel Medical City (Photo: AETOSWire)
    Prof. Horace Roman, a renowned endometriosis surgeon and founding member of IFEM Endo, will be heading the institute.
  • “The institute showcases our commitment to excellence and cements our position as a leader in complex care.

Mount Sinai Brooklyn Expands Cancer Services, Infusion Center in $4 Million Project

Retrieved on: 
Friday, May 19, 2023

NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) -- The Mount Sinai Health System today held a grand opening of the expansion of the Mount Sinai Brooklyn Ambulatory Infusion Center, a cancer treatment center that brings innovative cancer therapy and clinical trials to residents of southern Brooklyn.

Key Points: 
  • NEW YORK, May 19, 2023 (GLOBE NEWSWIRE) -- The Mount Sinai Health System today held a grand opening of the expansion of the Mount Sinai Brooklyn Ambulatory Infusion Center, a cancer treatment center that brings innovative cancer therapy and clinical trials to residents of southern Brooklyn.
  • Additionally, we are particularly grateful to the City Council for their generous contribution for the MRI scanner that furthers our mission of serving our patients equitably.”
    An extension of the Mount Sinai Tisch Cancer Center and The Tisch Cancer Institute, the National Cancer Institute-designated cancer center at the Icahn School of Medicine at Mount Sinai, the Mount Sinai Brooklyn Ambulatory Infusion Center gives patients access to the latest treatment options, medication protocols, and clinical trials.
  • “We are continuing to invest in our community and enhancing our health care services.”
    Luis Isola, MD, Director of Cancer Clinical Programs and Medical Director of Mount Sinai Cancer Network, added, “Mount Sinai Brooklyn Ambulatory Infusion Center is a demonstration of Mount Sinai’s commitment to delivering outstanding cancer care to local New York communities.
  • As part of the celebration, Mount Sinai Brooklyn offered onsite screenings for residents at the Mount Sinai Health System Mammogram Mobile Unit and the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit.

Mount Sinai Brooklyn Expands Cancer Services, Infusion Center in $4 Million Project

Retrieved on: 
Friday, May 19, 2023

NEW YORK, May 19, 2023 /PRNewswire-PRWeb/ -- The Mount Sinai Health System today held a grand opening of the expansion of the Mount Sinai Brooklyn Ambulatory Infusion Center, a cancer treatment center that brings innovative cancer therapy and clinical trials to residents of southern Brooklyn.

Key Points: 
  • The Mount Sinai Health System today held a grand opening of the expansion of the Mount Sinai Brooklyn Ambulatory Infusion Center, a cancer treatment center that brings innovative cancer therapy and clinical trials to residents of southern Brooklyn.
  • NEW YORK, May 19, 2023 /PRNewswire-PRWeb/ -- The Mount Sinai Health System today held a grand opening of the expansion of the Mount Sinai Brooklyn Ambulatory Infusion Center, a cancer treatment center that brings innovative cancer therapy and clinical trials to residents of southern Brooklyn.
  • An extension of the Mount Sinai Tisch Cancer Center and The Tisch Cancer Institute, the National Cancer Institute-designated cancer center at the Icahn School of Medicine at Mount Sinai, the Mount Sinai Brooklyn Ambulatory Infusion Center gives patients access to the latest treatment options, medication protocols, and clinical trials.
  • Luis Isola, MD, Director of Cancer Clinical Programs and Medical Director of Mount Sinai Cancer Network, added, "Mount Sinai Brooklyn Ambulatory Infusion Center is a demonstration of Mount Sinai's commitment to delivering outstanding cancer care to local New York communities.

Aspira Women’s Health launches its New to The Street Media Series on May 8, 2023, World Ovarian Cancer Day

Retrieved on: 
Monday, May 15, 2023

The first filming with AWH occurred on World Ovarian Cancer Day, May 8, 2023.

Key Points: 
  • The first filming with AWH occurred on World Ovarian Cancer Day, May 8, 2023.
  • In this segment, Jane and Nicole talk about AWH’s history as a leading innovator of advanced diagnostic solutions to improve health outcomes for women facing ovarian cancer and other gynecologic disease.
  • Nicole states, "Ovarian cancer is the deadliest gynecological cancer.
  • Airings should bring attention to the business fundamentals and ongoing successes at Aspira Women Health's and its blood tests to detect ovarian cancer.

Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023

Retrieved on: 
Monday, May 8, 2023

“While survival rates for ovarian cancer are creeping up to the 50% level, it is clear that the vast majority of women are diagnosed too late,” said Sanj Singh , CEO of Temple Therapeutics.

Key Points: 
  • “While survival rates for ovarian cancer are creeping up to the 50% level, it is clear that the vast majority of women are diagnosed too late,” said Sanj Singh , CEO of Temple Therapeutics.
  • Risk of death among ovarian cancer patients with more cytoplasmic than nuclear LMTK3 levels was particularly high during the first year after diagnosis.
  • We knew then this may be a game changer for ovarian cancer because it was present in all major subtypes.
  • “The addition of a companion diagnostic for early detection, therapeutic impact, and disease progression injects much-needed hope for ovarian cancer patients.

OVARIAN CANCER LEADERS URGE GENETIC TESTING FOR INCREASED-RISK INDIVIDUALS, AND CONSIDERATION OF PROPHYLACTIC SURGERY FOR ALL WOMEN

Retrieved on: 
Wednesday, February 1, 2023

Until there is a cure, these are our best weapons in the battle against ovarian cancer.

Key Points: 
  • Until there is a cure, these are our best weapons in the battle against ovarian cancer.
  • "Ovarian cancer is considered a rare disease, but for those with a family history and/or genetic mutation, the risk jumps to 40-50% or even higher.
  • "This is incredibly hard information to accept and runs contrary to almost all messaging related to ovarian cancer awareness to date.
  • However, to ignore learnings gained from current research would be detrimental to the wellbeing of women and the future of ovarian cancer research," said Moran.